Work at Ventus Therapeutics US Inc. has led to the identification of new caspase-4 allosteric and/or caspase-5 inhibitors reported to be useful for the treatment of sepsis, stroke, myocardial infarction, acute respiratory distress syndrome, inflammatory bowel disease, hidradenitis suppurativa, diabetic nephropathy and diabetic retinopathy, among others.

Rapt Therapeutics Inc. has patented new fused ring imidazole compounds acting as TNF-α modulators and thus reported to be useful for the treatment of cancer, pain, metabolic and autoimmune disease, inflammation, neurological, cardiovascular and eyes disorders.

A University of Texas System patent describes new radiolabeled positron emission tomography (PET) imaging agents targeting receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1). As such, they are potentially useful for the diagnosis of cancer, retinal and autoimmune diseases, neurological and inflammatory disorders.

Chengdu Sibeibo Pharmaceutical Technology Co. Ltd. has reported new poly(ADP-ribose) polymerase 14 (PARP-14; ARTD8) inhibitors potentially useful for the treatment of cancer, asthma, atopic dermatitis and infectious pneumonia.

Sichuan University has identified new G-protein coupled receptor 65 (GPR65) antagonists potentially useful for the treatment of cancer and epilepsy.

Aconcagua Bio Inc. has divulged new calcitonin (CALCR; CT-R) and amylin receptor agonists intended for use in the treatment of pain, neurodegeneration, bone, metabolic and cardiovascular disorders.

The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has synthesized new polycyclic heteroaryl compound acting as glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of diabetes and obesity, among others.

Helmholtz Zentrum München Universität Hannover has disclosed new heterocyclic compounds designed for use in the treatment of cancer and viral infection.

Uppthera Inc. has patented new NLRP3 inflammasome inhibitors potentially useful for the treatment of cancer, metabolic and autoimmune diseases, cardiovascular, inflammatory, neurological, renal and respiratory disorders, among others.

Ensem Therapeutics Inc. has divulged new bicyclic heteroaryl and heterocyclic compounds acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors potentially useful for the treatment of cancer.